The real industrial eternal power of Innovative Potential comes from its ability to create new molecular applications through the electrochemical activation mechanism.

 

For antibiotics like Penicillin: the scale and volume of antibiotic use for eight (8) billion people is driving global antibiotic resistances and deaths. The World Health Organization currently estimates that nearly 4.95 million people die per year due to associated antimicrobial resistant infections [1]. However, if you were to protect existing antimicrobials with a CGP-specific chaperone, one that microbes cannot metabolize, and prevent the development of antimicrobial resistant strains of microorganisms: you can retain the effectiveness of your limited selection of antimicrobials longer.

 

Having antimicrobial effects achieved only via CGP-use allows for:

• antimicrobial resistance development to be slowed; and,

• the reserve-line antimicrobials can be better protected; and,

• new forms of antimicrobials can be developed.

​

This self-same activation principle holds true for several other medical and non-medical molecule classes like pain-killers; disinfectants; epoxies; glues and adhesives; additional oncologics; pesticides; demolition and explosive agents; colorful dyes and printer inks; and, even food flavors and ingredients.

​

There almost is no limit with Innovative Potential and CGP molecular strategies, only increased control. How much control? Total.

 

Innovative Potential can turn cancer itself into cures.

​

1. World Health Organization. Antimicrobial Resistance. 2025. <https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance>.